SCHEMBL6702893

SCHEMBL6702893

CC(C)(N)CNc1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.52
FABP1 P07148 1/20 0.50
FABP6 P51161 1/20 0.50
CYP2C19 P33261 1/20 0.50
CYP1A2 P05177 1/20 0.47
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
GAA P10253 2/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
CYP2D6 P10635 1/20 0.44
NOS1 P29475 1/20 0.43
FDPS P14324 1/20 0.42
MEN1 O00255 1/20 0.42
MAPK10 P53779 1/20 0.42
GFER P55789 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29846927 0.85 CXCR4 (0.55) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL278768 0.85 CXCR4 (0.55) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL4718056 0.82 CXCR4 (0.49) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL21210525 0.82 CXCR4 (0.45) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL17700674 0.81 CXCR4 (0.52) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL7383486 0.81 CXCR4 (0.52) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL17700372 0.81 CXCR4 (0.52) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL17700596 0.81 CXCR4 (0.56) CXCR4FABP1FABP6CYP2C19CYP1A2
Hydrochloric Acid SCHEMBL17700125 0.80 CXCR4 (0.50) CXCR4FABP1FABP6CYP2C19CYP1A2
SCHEMBL17700790 0.79 CXCR4 (0.49) CXCR4FABP1FABP6CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3031799-B1 AROMATIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-04-04 EP disclosed
US-9776962-B2 Aromatic compounds with GPR40 agonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
EP-3031799-A1 AROMATIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-15 EP disclosed
EP-3013827-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-05-04 EP disclosed
US-20160115128-A1 AROMATIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-04-28 US disclosed
WO-2014206345-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 WO disclosed
US-20040180925-A1 Dipeptidylpeptidase-IV inhibitor KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-16 US disclosed
EP-1354882-A1 DIPEPTIDYL PEPTIDASE IV INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115128-A1 AROMATIC COMPOUND GLP1R, GPR119, GPR39 CXCR4 1021/4885FABP1 66/4885FABP6 35/4885
US-20040180925-A1 Dipeptidylpeptidase-IV inhibitor DPP4, DPP3, DPP9 CXCR4 2747/4885FABP1 434/4885FABP6 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.